Investor enthusiasm for Gradalis Inc.'s autologous vaccine platform, Furin-ANd-GMCSF (FANG), boosted what began as a $10 million or so Series B round to an amount more than twice that much, and the firm will use the $24 million to move the Phase II ovarian cancer therapy along while expanding manufacturing capabilities.